TipRanks
Advertisement
Advertisement

CABA Stock Latest News

Why is Caribou Biosciences Stock (CRBU) Down 43% Today?
Market NewsWhy is Caribou Biosciences Stock (CRBU) Down 43% Today?
12d ago
CABA
CRBU
Cabaletta Bio Boosts Cash Through Warrant Exercises
PremiumCompany Announcements
Cabaletta Bio Boosts Cash Through Warrant Exercises
1M ago
8K
CABA
Cabaletta Bio reports Q2 EPS (34c), consensus (34c)
PremiumThe Fly
Cabaletta Bio reports Q2 EPS (34c), consensus (34c)
2M ago
CABA
3 High-Risk, High-Reward Stocks to Buy Now for Strong Upside, According to Analysts
PremiumMarket News
3 High-Risk, High-Reward Stocks to Buy Now for Strong Upside, According to Analysts
3M ago
NNE
ONT
Cabaletta Bio Hits Reset on RESET-MS Trial, Narrowing Near-Term Upside in Multiple Sclerosis
PremiumCompany Announcements
Cabaletta Bio Hits Reset on RESET-MS Trial, Narrowing Near-Term Upside in Multiple Sclerosis
4M ago
CABA
Cabaletta Bio Shareholders Approve Share Increase and Directors
PremiumCompany AnnouncementsCabaletta Bio Shareholders Approve Share Increase and Directors
4M ago
8K
CABA
Buy Rating Reaffirmed on Robust Rese‑cel Autoimmune Data; $13 Price Target Reiterated as Cabaletta Advances Toward Commercialization
Premium
Ratings
Buy Rating Reaffirmed on Robust Rese‑cel Autoimmune Data; $13 Price Target Reiterated as Cabaletta Advances Toward Commercialization
5M ago
CABA
Cabaletta Bio: Buy Rating Reiterated as Rese-cel Data Strengthen Outpatient Cell Therapy Thesis; $16 Price Target Maintained
Premium
Ratings
Cabaletta Bio: Buy Rating Reiterated as Rese-cel Data Strengthen Outpatient Cell Therapy Thesis; $16 Price Target Maintained
5M ago
CABA
Cabaletta Bio presents new data for rese-cel in autoimmune diseases
PremiumThe Fly
Cabaletta Bio presents new data for rese-cel in autoimmune diseases
5M ago
CABA
Cabaletta Bio Highlights Rese-cel Data and Pivotal Path
PremiumCompany Announcements
Cabaletta Bio Highlights Rese-cel Data and Pivotal Path
5M ago
8K
CABA
Douglas Tsao Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target on Rese-cel’s Emerging Commercial Profile and Conditioning-Free Edge
PremiumRatings
Douglas Tsao Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target on Rese-cel’s Emerging Commercial Profile and Conditioning-Free Edge
5M ago
CABA
Analyst Reiterates Buy on Cabaletta Bio Citing Strong Cash Runway and Promising Early Rese-cel Data in Autoimmune Diseases
PremiumRatings
Analyst Reiterates Buy on Cabaletta Bio Citing Strong Cash Runway and Promising Early Rese-cel Data in Autoimmune Diseases
5M ago
CABA
Analyst Reiterates Buy on Cabaletta Bio, Citing Strong Non-Preconditioned PV Data, Scalable Manufacturing, and Multiple Upcoming Catalysts
PremiumRatingsAnalyst Reiterates Buy on Cabaletta Bio, Citing Strong Non-Preconditioned PV Data, Scalable Manufacturing, and Multiple Upcoming Catalysts
5M ago
CABA
Cabaletta Bio presents new clinical data for rese-cel
Premium
The Fly
Cabaletta Bio presents new clinical data for rese-cel
5M ago
CABA
Cabaletta Bio reports Q1 EPS (39c), consensus (39c)
Premium
The Fly
Cabaletta Bio reports Q1 EPS (39c), consensus (39c)
5M ago
CABA
Cabaletta Bio Reports Encouraging RESET-PV Trial Data
PremiumCompany Announcements
Cabaletta Bio Reports Encouraging RESET-PV Trial Data
5M ago
8K
CABA
Cabaletta Bio Maintained at Buy as Emerging Rese-cel Data Support Preconditioning-Free Potential; $13 Price Target Reaffirmed
PremiumRatings
Cabaletta Bio Maintained at Buy as Emerging Rese-cel Data Support Preconditioning-Free Potential; $13 Price Target Reaffirmed
6M ago
CABA
Cabaletta Bio financing overhang concerns should be addressed, says Cantor
PremiumThe Fly
Cabaletta Bio financing overhang concerns should be addressed, says Cantor
6M ago
CABA
Cabaletta Bio Announces $150 Million Equity Offering
PremiumCompany Announcements
Cabaletta Bio Announces $150 Million Equity Offering
6M ago
8K
CABA
Cabaletta Bio reports promising RESET-PV and RESET-SLE data
PremiumCompany AnnouncementsCabaletta Bio reports promising RESET-PV and RESET-SLE data
6M ago
8K
CABA
Cabaletta Bio: Buy Rating Reiterated as Rese-cel Data and Cellares Partnership Support Unchanged $16 Price Target
Premium
Ratings
Cabaletta Bio: Buy Rating Reiterated as Rese-cel Data and Cellares Partnership Support Unchanged $16 Price Target
6M ago
CABA
Cabaletta Bio, Cellares report 10-year commercial supply agreement for rese-cel
Premium
The Fly
Cabaletta Bio, Cellares report 10-year commercial supply agreement for rese-cel
6M ago
CABA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >